Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q1 FY2025 Earnings Presentation
34 slides from Jubilant Ingrevia's earnings presentation, July 2024
Slide 1: Investor Presentation
Jubilant Ingrevia Limited Investor Presentation July 2024 1
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Chairmen's Message on Q1'FY25 Financial Results | 1/2
Chairmen’s Message on Q1’FY25 Financial Results | 1/2 “We are pleased to announce healthy sequential performance for Q1, on the back of the improving business performance of our Speciality Chemical Business and the positive impact coming from our cost initiatives from the last three quarters. Market
Slide 4: Chairmen's Message on Q1'FY25 Financial Results | 2/2
Chairmen’s Message on Q1’FY25 Financial Results | 2/2 USFDA Update: We are pleased to share that our manufacturing facility at Bharuch has successfully completed its USFDA inspection with Zero 483 observation. This GMP-compliant facility is intended for manufacturing of Nutraceuticals & Dietary- Act
Slide 5: Table of Contents
Table of Contents 0 6 Company Overview 1 0 Growth Roadmap 1 3 Q1’FY25 Highlights 1 8 Business Segments and Enablers Update 5
Slide 6: Company Overview
Company Overview Niacinamide plant at Bharuch, Gujarat successfully receives Establishment Inspection Report (EIR) from USFDA with Zero 483 observations 66
Slide 7: Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group
Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group 45+ years 2300+ people 3rd largest of legacy in Chemicals space, started with strong leadership team with Company in the Jubilant Group average 25+ years of experience in in 1978 as VAM Organic Chemicals Chemicals sp
Slide 8: Our business is split across 3 business verticals, with global leadership across key product lines
Our business is split across 3 business verticals, with global leadership across our key product lines 42% Revenue Mix 18% Revenue Mix 40% Revenue Mix 59% EBITDA Mix # 16% EBITDA Mix # 25% EBITDA Mix # Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates CDMO (Pharma, Agro, Semi
Slide 9: We serve customers across geographies and sectors
We serve customers across geographies and sectors; increased growth from exports and pharma/cosmetic/nutrition sectors in recent years Our Product Platforms Enable us to serve diverse customer segments and market needs 1• Pyridine Geographical Revenue Split End-use Industry Revenue Split 2• Diketene
Slide 10: Growth Roadmap (Recap)
Growth Roadmap (Recap) 10 10
Slide 11: Our new 'Compass' forms the bedrock of our future growth roadmap
Our new ‘Compass’ forms the bedrock of our future growth roadmap PURPOSE VISION Enable a Sustainable World through Leading provider of innovative solutions Chemistry in our core chemistries globally Customer Centricity World-class, Safe Innovation & ESG Leader People Focused Operations Technology Cu
Slide 12: Recap: Future Growth Aspiration to grow 3x in next years
Recap: Future Growth Aspiration to grow 3x in next 5 years PINNACLE 3.4.5 12
Slide 13: Recap: Building blocks of Pinnacle
Recap: Building blocks of Pinnacle 345 JUBILANT INGREVIA FULL POTENTIAL 3X revenue, 4X EBITDA, 5 years GROWTH PILLARS A Specialty Chemicals B Nutrition & Health solutions C Chemical Intermediates Pyridine & Picoline Retain Global leadership (#1 position, cost leadership) Animal Nutrition Acetic Anhy
Slide 14: Recap: Pinnacle 345: Key Growth Priorities
Recap: Pinnacle 345: Key Growth Priorities Future Priorities Portfolio Higher focus on specialty products (downstream value-added products (n-1, n-2), CDMO, nutrition) Higher focus on US/Japan markets and Pharma/Cosmetics/Nutrition sectors Approach/ “Customer-centric” approach Mindset (everything st
Slide 15: Q1'FY25 Highlights
Q1’FY25 Highlights 15 15
Slide 16: Market Overview: Q1'FY25 | Gradual recovery in volumes across segments
Market Overview: Q1’FY25 | Gradual recovery in volumes across segments; prices are still largely muted with some green shoots PHARMA • Steady demand with good visibility on volumes across segments; volume growth seen in both Pyridine and Diketene derivatives • Stability in prices across segments; up
Slide 17: Key business highlights Q1FY25
Key business highlights Q1FY25: Continuing progress in line with our long-term strategy • Pyridine & Picoline: Significant volume growth on YoY basis; prices inching up sequentially; Core product platforms continue to world’s largest and only non-Chinese scaled player in Pyridine drive growth and le
Slide 18: Financial Results Overview | Q1'FY25 Consolidated
Financial Results Overview | Q1’FY25 Consolidated 1 Particulars Q1'FY24 Q4'FY24 Q1'FY25 Q-o-Q Y-o-Y Total Revenue 1,075 1,074 1,024 -5% -5% Total EBITDA 125 101 119 18% -5% EBITDA Margin (%) 12% 9% 12% Profit After Tax 58 29 49 67% -15% Profit After Tax Margin (%) 5% 3% 5% Basic and Diluted EPS (Rs.
Slide 19: Positive momentum building up in Specialty and Nutrition
We have started to see positive momentum building up in Specialty and Nutrition Specialty Chemicals Nutrition & Health Solutions EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 50% Y.o.Y Growth 37% Q.o.Q Growth 28% Q.o.Q Growth 165% 86 23 67 17 57 9 16% 14% 20% 8% 5% 12% Q1 FY24 Q4 FY24 Q1 FY25 Q1 FY24
Slide 20: Business Segments Overview
Business Segments Overview 20 20
Slide 21: Specialty Chemicals | Market, Business & Financial Highlights
1 Specialty Chemicals | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Steady demand from the end-use segment, Particulars 1 Q1'FY24 Q4'FY24 Q1'FY25 Q-o-Q Y-o-Y volumes were strong and prices witnessed a marginal uptick Segment Revenue 364 475 431 -9% 18% Pharma % Sha
Slide 22: Nutrition & Health Solutions | Market, Business & Financial Highlights
2 Nutrition & Health Solutions | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS 1 Vitamin demand remained stable during the Particulars Q1'FY24 Q4'FY24 Q1'FY25 Q-o-Q Y-o-Y quarter, though overall Niacinamide pricing Segment Revenue 202 165 186 13% -8% remained steady
Slide 23: Chemical Intermediates | Market, Business & Financial Highlights
3 Chemical Intermediates | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Ethyl Acetate Volumes improved on good 1 demand in the export market. Particulars Q1'FY24 Q4'FY24 Q1'FY25 Q-o-Q Y-o-Y Acetic Acid Volumes remained steady Segment Revenue 509 435 408 -6% -20% Key
Slide 24: Annexures
JUBILANT INGREVIA
Slide 25: Group Overview
Group Overview Indian conglomerate with global presence, with USD 6Bn market cap and ~USD 2.5Bn revenue Established presence in diversified sectors, e.g., Agro and Pharma Intermediates, Jubilant Bhartia CDMO, Therapeutics, Speciality Chemicals, Nutrition, Food Service (QSR), Auto Group founded by Em
Slide 26: Efficiencies through Multi Location Manufacturing & Operation Excellence
Efficiencies through Multi Location Manufacturing & Operation Excellence Overview of Manufacturing Facilities Gajraula, Bharuch, Nira, Savli, Ambernath, Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for Agro-Actives and Agro- Chemical In
Slide 27: Established R&D Capabilities across multiple chemistry platforms
Established R&D Capabilities across multiple chemistry platforms Key 3 R&D centers in Noida, Gajraula 35 Key technology platforms developed & commercialized to and Bharuch global standards. Some are unique: Ammoxidation, Grignard etc. Highlights 131 highly qualified scientists (26 PhDs) 40+ Products
Slide 28: Sustainability: #2 in ESG rankings in Indian Chemical Industry
Sustainability: #2 in ESG rankings in Indian Chemical Industry • Received Gold Rating Bharuch Nira Gajraula • Achieved (Dec 2018) (Oct 2019) (Oct 2021) 95 percentile (Score 73/100) 157/200 164/200 186/200 Participated in S&P DJSI Assessment: (79%) (82%) (93%) Global chemical Climbed from 23rd • Achi
Slide 29: Bringing Progressive Social Change via Strategic Multi-Stakeholder Partnerships
Bringing Progressive Social Change via Strategic Multi-Stakeholder Partnerships Established Mission: To develop multi-stakeholder sustainable models to 1 Aspiring to touch the Lives in 2007 bring about ‘social change’ involving knowledge generation & Million sharing, experiential learning & entrepre
Slide 30: Annexure I - Income Statement | Consolidated – Q1'FY25
Annexure I - Income Statement | Consolidated – Q1‘FY25 Particulars1 Q1'FY24 Q4'FY24 Q1'FY25 QoQ YoY Revenue from operations a) Sales/Income from operations 1069 1060 1010 -5% -5% b) Other operating income 6 14 14 -2% 118% Total revenue from operations 1075 1074 1024 -5% -5% Other income 9 10 10 1% 1
Slide 31: Annexure II: Income Statement Segmental – Q1'FY25
Annexure II: Income Statement Segmental – Q1’FY25 Particulars1 Q1'FY24 Q4'FY24 Q1'FY25 QoQ (%) YoY (%) Revenue Speciality Chemicals 364 475 431 (9%) 18% Nutrition & Health Solutions 202 165 186 13% (8%) Chemical Intermediates 509 435 408 (6%) (20%) Total Revenue from Operations 1,075 1,074 1,024 (5%
Slide 32: Annexure III: Debt Position | As on 30th June 2024
Annexure III: Debt Position| As on 30th June 2024 1 Particulars 30-Jun-23 31-Mar-24 30-Jun-24 Long Term Borrowings 150 450 450 Short Term Borrowings 404 283 291 Total Gross Debt 554 733 741 Cash & Equivalent 62 80 64 Total Net Debt 492 653 677 YoY change 38% • The capex for the quarter was Rs 116 Cr
Slide 33: Annexure III - Conference Call Details
Annexure III - Conference Call Details Diamond Pass Log-In Date : July 16th, 2024 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, pass
Slide 34: Thank you for your time
For More Information For Investors: Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pavleen Taneja Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions Jubilant Ingrevia Limi